earn	smithkline skb aims for pct earnings raise smithkline beckman corp pursuing point stragey that will achieve pct annual increase operating earnings remainder decade smithkline earned mln dlrs dlrs per share revenues billion dlrs company annual report that nonpharmaceutical business will play major role meeting earnings growth target and will fact grow faster pharmaceutical business smithkline major product antiulcer medication tagamet report that intends improve earnings existing products expand product portfolio and optimize financial resources bolster position antiulcer market tagamet met stiff competition smithkline strategy develop counter version tagamet bolstered two joint ventures wellcome plc and pending venture japan smithkline allergan inc eye and skin care products division can billion dlr organization years that can grow pct annually nondilutive acquisitions real possibility gavin herbert president eye and skin care product group report allergan had worldwide sales mln dlrs smith kline and french laboratories pharmaceuticals unit sales billion dlrs will file for food and drug administration marketing approval for number cardiovascular agents including tissue plasminogen activator two years and sales force will pct larger sales personnel smith kline small clinical laboratory testing unit sales mln dlrs performs mln tests year and sees increases employee drug testing testing for aids antibody smith kline that depending share price and cost money buy back shares last years bought back pct shares smithkline begins year management team including chief operating officer george ebright InformationRetrieval.reuter